Luke Gabe, MD
Pulmonary Disease · Santa Fe, NMNPI 1902199797
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,304 of the $47,130 with a category attached, or 64.3%. Mylan Specialty L.p. accounts for 65.9% of it on its own, with 23 other manufacturers making up the rest. Among pulmonary disease clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $392.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$31K
- Viatris Specialty LLC$10K
- Intuitive Surgical$4K
- AstraZeneca$371
- United Therapeutics Corporation$227
- Veran Medical Technologies, Inc.$137
- plus $727 from 18 others
What the payments were for
- Consulting fees$7,95617%
- Speaking & faculty fees$30,30464%
- Travel & lodging$4,69110%
- Food & beverage$2,5465%
- Education$1,6333%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 44 | $31,054 |
| Viatris Specialty LLC | 10 | $10,357 |
| Intuitive Surgical | 18 | $4,257 |
| AstraZeneca | 10 | $371 |
| United Therapeutics Corporation | 2 | $227 |
| Veran Medical Technologies, Inc. | 2 | $137 |
| Boehringer Ingelheim | 8 | $125 |
| GSK | 6 | $111 |
| Genentech USA, Inc. | 1 | $100 |
| Noah Medical Corporation | 1 | $43 |
| Abiomed | 1 | $39 |
| Merit Medical Systems Inc | 1 | $37 |
| Grifols USA, LLC | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Chiesi USA, Inc. | 2 | $28 |
| Olympus America Inc. | 2 | $27 |
| Pulmonx Corporation | 1 | $24 |
| Ambu Inc. | 1 | $22 |
| Circassia Inc. | 1 | $19 |
| CSL Behring | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$40,719
- Da Vinci Surgical System$3,962
- TEZSPIRE$125
- Spin$122
- FASENRA$117
How this compares
$47,130 in reported general payments places this provider in the 95th percentile of 56 pulmonary disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $223,744 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 77 | $68,527 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $59,653 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 69 | $48,488 |
| NucalaMepolizumab | 13 | $47,955 |
| Spiriva RespimatTiotropium Bromide | 54 | $42,420 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $28,174 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $22,161 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $14,605 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,657 |
| BreynaBudesonide/Formoterol Fumarate | 23 | $5,015 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $4,788 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $3,693 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,208 |
| Mycophenolate Mofetil | 11 | $1,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $125 | $314,652140 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $111 | $166,599144 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $371 | $83,132134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 pulmonary disease providers in New Mexico.
Other pulmonary disease in Santa Fe
- Elspeth SpringstedSanta Fe$275
- Matthew CroweSanta Fe$207
- Michael LuciaSanta Fe$204
- Bruce ShafferSanta Fe$132
- Wolfgang Schmidt-NowaraSanta Fe$48
- Lana Melendres GrovesAlbuquerque$1.1M
- Michelle HarkinsAlbuquerque$24K
- Viral GandhiAlbuquerque$14K
- Gonzalo DiazAlamogordo$14K
- Arjan FloraAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.